Nothing seems to bother Outlook Therapeutics (NASDAQ:OTLK)

Earnings results for Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics, Inc. is estimated to report earnings on 02/12/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.29.

Outlook Therapeutics last posted its quarterly earnings data on December 22nd, 2020. The reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.05. Outlook Therapeutics has generated ($0.67) earnings per share over the last year. Outlook Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, February 12th, 2021 based off prior year’s report dates.

Analyst Opinion on Outlook Therapeutics (NASDAQ:OTLK)

4 Wall Street analysts have issued ratings and price targets for Outlook Therapeutics in the last 12 months. Their average twelve-month price target is $6.33, predicting that the stock has a possible upside of 144.53%. The high price target for OTLK is $8.00 and the low price target for OTLK is $5.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Outlook Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $6.33, Outlook Therapeutics has a forecasted upside of 144.5% from its current price of $2.59. Outlook Therapeutics has received no research coverage in the past 90 days.

Dividend Strength: Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics does not currently pay a dividend. Outlook Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Outlook Therapeutics (NASDAQ:OTLK)

In the past three months, Outlook Therapeutics insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $11,360,000.00 in company stock and sold $0.00 in company stock. Only 4.00% of the stock of Outlook Therapeutics is held by insiders. Only 3.04% of the stock of Outlook Therapeutics is held by institutions.

Earnings and Valuation of Outlook Therapeutics (NASDAQ:OTLK

The P/E ratio of Outlook Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Outlook Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Outlook Therapeutics has a P/B Ratio of 129.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here